P2Y12 Inhibitor or Aspirin Monotherapy for Chronic Coronary Disease: A Nationwide Cohort Study
Minyoul Baik, Jimin Jeon, Joonsang Yoo, Jinkwon Kim · 2025
Read P2Y12 Inhibitor or Aspirin Monotherapy for Chronic Coronary Disease: A Nationwide Cohort Study by Minyoul Baik, Jimin Jeon, Joonsang Yoo, Jinkwon Kim (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12721736.txt.
Description
Baik, Jeon, Yoo, and Kim compare in 2025 two single drug options for long term care of chronic heart artery disease in Korea. A 2024 European guideline newly backed one drug class as a sound swap for aspirin. They tested that advice in a nationwide claims database.
Patients had stents placed from 2019 to 2023 and were checked 18 months later. Of about 127,000 patients, two thirds took the newer drug alone and one third took aspirin alone. After matching, about 42,700 pairs were compared over a median of three years. The newer drug did not cut the combined risk of death, heart attack, stroke, or major bleeding.
Catalog record
| CREATOR | Minyoul Baik, Jimin Jeon, Joonsang Yoo, Jinkwon Kim |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |